Losartan Therapy in Pulmonary Hypertension

Losartan Decreases Pulmonary Artery Pressure and Improves Exercise Capacity in Patients With Pulmonary Hypertension

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00519870

Enrollment

Unknown

Registered

2007-08-23

Start date

2005-01-31

Completion date

2005-07-31

Last updated

2007-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Keywords

Pulmonary hypertension, Angiotensin receptor blocker, Calcium channel blocker

Brief summary

In addition to being effective vasodilators, angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) exert neurohumoral inhibitory actions, such as the inhibition of vascular remodeling and smooth muscle cell proliferation and the amelioration of endothelial dysfunction. These beneficial effects, render those agents appropriate for use in the treatment of pulmonary hypertension. However, data regarding the use of ACEIs or ARBs in the treatment of PHT are limited. In this study, efficacy of an ARB, losartan was compared with those of the calcium channel blocker, nifedipine in the treatment of pulmonary hypertension using echocardiographic, 6-minute walk test (6MWT), cardiopulmonary exercise test, and endothelin-1 levels.Losartan is as effective as nifedipine for reducing Doppler echocardiographically measured PAP and improving exercise capacity on 6MWT and CPET. However the short-term use of losartan or nifedipine had no statistically significant effect on endothelin-1 levels in patients with PHT.

Interventions

DRUGnifedipine, losartan

I: nifedipine 30 mg/d II: losartan 50 mg/d

DRUGlosartan

II: losartan

DRUGNifedipine, losartan

I: nifedipine II: losartan

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Pulmonary hypertension diagnosed by Doppler echocardiographic examination (a mean pulmonary artery pressure of \> 26mmHg)

Exclusion criteria

* acute infectious or inflammatory disease, * exacerbation of chronic obstructive pulmonary disease, * malignancy, * acute coronary syndrome in the last 4 weeks, * uncontrolled arrhythmia and hypertension, * decompensated heart failure, * acute pulmonary emboli, * thrombus in a lower extremity, * oxygen saturation below 85% at rest, * failure to cooperate with CPET

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026